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Single CD28 stimulation induces 
stable and polyclonal expansion of 
human regulatory T cells
Xuehui He1,2, Ruben L. Smeets3, Esther van Rijssen1, Annemieke M. H. Boots4, Irma Joosten1 
& Hans J. P. M. Koenen1
CD4+FOXP3+ Treg are essential for immune tolerance. Phase-1 clinical trials of Treg-therapy to treat 
graft-versus-host-disease reported safety and potential therapeutic efficacy. Treg-based trials have 
started in organ-transplant patients. However, efficient ex vivo expansion of a stable Treg population 
remains a challenge and exploring novel ways for Treg expansion is a pre-requisite for successful 
immunotherapy. Based on the recent finding that CD28-signaling is crucial for survival and proliferation 
of mouse Treg, we studied single-CD28 stimulation of human Treg, without T cell receptor stimulation. 
Single-CD28 stimulation of human Treg in the presence of recombinant human IL-2(rhIL-2), as 
compared to CD3/CD28/rhIL-2 stimulation, led to higher expression levels of FOXP3. Although the 
single-CD28 expanded Treg population was equally suppressive to CD3/CD28 expanded Treg, pro-
inflammatory cytokine (IL-17A/IFNγ) production was strongly inhibited, indicating that single-CD28 
stimulation promotes Treg stability. As single-CD28 stimulation led to limited expansion rates, we 
examined a CD28-superagonist antibody and demonstrate a significant increased Treg expansion that 
was more efficient than standard anti-CD3/CD28-bead stimulation. CD28-superagonist stimulation 
drove both naïve and memory Treg proliferation. CD28-superagonist induction of stable Treg appeared 
both PI3K and mTOR dependent. Regarding efficient and stable expansion of Treg for adoptive Treg-
based immunotherapy, application of CD28-superagonist stimulation is of interest.
Regulatory T cells are crucial for immune homeostasis and tolerance. These cells are typically characterized by 
expression of the transcription factor FOXP3, and have been shown to play an important role in the prevention 
of graft-versus-host-disease (GvHD), transplantation rejection and autoimmunity1. Treg-based immunotherapy 
applying ex vivo expanded naturally occurring Treg (nTreg) prevented pathology in a wide variety of mouse models2–5. 
The prospects of these studies supported phase-I clinical trials of Treg-based cell therapy in stem cell transplan-
tation (SCT), which reported safety and potential therapeutic efficacy6–8. This success promoted the recent ini-
tiation of Treg-based immunotherapy in solid organ transplantation (The One Study, ThRIL). Notwithstanding 
the first successes in the translation of Treg therapy to the clinic, successful ex vivo expansion of a stable suppres-
sive Treg population in sufficient numbers still remains one of the key challenges in clinical practice in order 
to achieve full clinical efficacy. Combined T cell receptor (TCR)/CD3 stimulation and CD28 in the presence of 
exogenously added recombinant human IL-2 (rhIL-2) is commonly used to expand human Treg9,10. This proce-
dure can lead to high cell yields, but also revealed Treg plasticity, characterized by loss of FOXP3 and the ability 
of the Treg to convert into (pathogenic) pro-inflammatory cytokine (IL-17A and IFNγ ) secreting cells11–13. This 
prompted the search for agents that promote Treg stability. High level expression of FOXP3 is important for opti-
mal Treg function. This is maintained by hyper-demethylation of a noncoding CpG motif within the FOXP3 gene 
upstream of exon-1 that is referred to as the Treg-specific demethylated region (TSDR)14. The mTOR inhibitor 
rapamycin is often added to expansion cultures to enhance FOXP3 expression and prevent outgrowth of contam-
inating conventional T cells15–17. However, although rapamycin works favorably on Treg function, addition of 
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rapamycin generally leads to lower overall Treg cell yields17. Therefore, there is a need for novel approaches that 
yield high numbers as well as highly suppressive and stable Treg.
It is well appreciated that CD28 stimulation plays an important role in the development of FOXP3+ cells in 
the thymus18,19. Notably, recent data obtained in Treg-specific CD28 conditional knockout mice, indicates that 
CD28 signaling is also crucial for peripheral Treg survival, proliferation and suppressor function20. The intrinsic 
CD28 deficiency in peripheral Treg resulted in autoimmunity that could be prevented by supplementation with 
CD28-sufficient Treg20. In rodent models it was demonstrated that CD28 stimulation promotes expansion of 
CD4+ CD25+ Treg21,22. Interestingly, artificial antigen-presenting cells modified to express the natural CD28 
ligand CD86, as compared to anti-CD3/anti-CD28 bead stimulation induced superior proliferation of human 
cord blood derived Treg23. Recently, Tabares et al. showed that in vitro stimulation of human PBMC by low-dose 
CD28 superagonist (TGN1412) selectively activated Treg24. We hypothesize that CD28 signaling in the absence 
of CD3 stimulation might play an important role in human Treg homeostasis and that single-CD28 stimulation 
might drive stable expansion of human Treg, to be used for Treg-based immunotherapy. Here, we demonstrate 
that single-CD28 stimulation in the absence of TCR (CD3) stimulation, but in the presence of exogenously added 
rhIL-2 promotes superior FOXP3 expression and prevents the production of pro-inflammatory cytokines IL-17A 
and IFNγ . The use of CD28-superagonistic mAbs further promotes polyclonal Treg expansion, to even higher lev-
els as observed in case of classical CD3/CD28 stimulation. The mechanism resulting in CD28-superagonist medi-
ated Treg stability depends on differential PI3K and mTOR signaling, since selective PI3K-inhibition restores the 
cytokine producing potential while mTOR inhibition led to reduced FOXP3 expression levels.
Results
Single-CD28 stimulation of FACS-sorted CD4+CD25high Treg induces proliferation and high 
level expression of FOXP3. To assess the ability of single-CD28 stimulation to stimulate human Treg pro-
liferation, highly purified FACS-sorted human CD4+ CD25high Treg were labeled with CFSE and stimulated with 
soluble CD28 monoclonal antibody (mAb), plate-bound CD3 mAb or both in the presence of rhIL-2 for 7-days. 
Thereafter, the cell division of Treg as indicated by the dilution of CFSE was determined using flow cytometry. 
Single-CD28 stimulation in the absence of T cell receptor ligation was indeed capable to drive Treg proliferation 
(44.1% ± 19.2, mean ± SD, Fig. 1a). Combined plate-bound CD3 plus soluble CD28 mAb (anti-CD3+ CD28) 
stimulation resulted in the highest level of proliferation. Intriguingly, the dividing Treg that were observed fol-
lowing CD28 stimulation showed higher FOXP3 expression levels at day 7 of culture (MFI, 65.6 ± 19.1) than the 
dividing Treg that were observed following anti-CD3 (MFI, 35.6 ± 8.5) or anti-CD3+ CD28 (MFI, 23.1 ± 12.9, 
mean ± SD, Fig. 1b) stimulation. As it has recently been shown that CD28 signaling is required for post thymic 
survival and proliferation of mouse Treg20, we analyzed if single-CD28 stimulation in the absence of CD3 stim-
ulation influenced Treg survival by measuring the intracellular expression of active caspase-3 as an indicator of 
Treg cell apoptosis. Indeed, single-CD28 stimulation in the presence of exogenously added rhIL-2 resulted in a 
slightly lower, albeit not significant, percentage of apoptotic cells as compared to anti-CD3+ CD28 stimulated 
Treg (Fig. 1c).
Single-CD28 stimulated Treg maintain suppressive capacity and TSDR demethylation. Thymus 
derived Treg contain a highly demethylated TSDR, which is crucial for maintaining a stable level of FOXP3 
expression and suppressor capacity14. To explore if single-CD28 stimulation modifies the methylation status of 
the TSDR, bisulphite sequencing was applied. CD28-stimulated Treg revealed a tendency towards higher levels 
of TSDR hyper-demethylation (demethylation index 0.97 ± 0.16) as compared to CD3+ CD28 (0.77 ± 0.22) or 
CD3-stimulated (0.62 ± 0.36, mean ± SD, Fig. 2a) Treg. To assess if these expanded Treg maintained their sup-
pressive capacity, CFSE-labeled FACS-sorted Treg were stimulated using CD28 or CD3 (for comparison) in the 
presence of rhIL-2, and the dividing Treg population, as indicated by the CFSE-dilution, was FACS-sorted at day 
7 and analyzed for their suppressor capacity using CFSE-based co-culture suppression assays. Both CD28- and 
CD3- expanded Treg preserved their capacity to suppress the proliferation of responder cells (Fig. 2b).
Single-CD28 stimulated Treg have a reduced pro-inflammatory cytokine producing potential. 
In recent years, it has become clear that FOXP3+ Treg may show functional plasticity as indicated by their 
capacity to produce pro-inflammatory cytokines such as IL-17A and IFNγ under specific microenvironmen-
tal stimuli11,12,25. Thus, we analyzed the IL-17A and IFNγ producing potential of human FACS-sorted Treg that 
were stimulated with single-CD28 or anti-CD3+ CD28 mAb. Single-CD28 stimulated Treg revealed lower per-
centages of IL-17A producing cells, as compared to anti-CD3+ CD28 (2.2% ± 2, versus 10.3% ± 8 for CD3+ 
CD28, mean ± SD), and these cells hardly produced IFNγ (1.7% ± 1.5, mean ± SD, Fig. 2c). This indicates that 
single-CD28 stimulation mediated expansion of human Treg results in a Treg population with increased stability 
as compared to anti-CD3+ CD28 expanded Treg.
CD28-superagonist stimulation promotes a stable Treg phenotype and leads to profound 
polyclonal Treg expansion. Using a CD28-agonistic mAb and exogenously added rhIL-2, we showed that 
stimulation of Treg with this CD28-agonist led to a Treg population with increased stability and good suppressor 
function, but lacked in full induction of proliferation. To improve this latter aspect, we stimulated Treg with the 
CD28-superagonist mAb ANC28.1, a strong inducer of human conventional T cell proliferation26. Indeed, as 
compared to CD28-agonist stimulation, CD28-superagonist stimulation led to a superior expansion of Treg, to 
a level significantly higher than that observed upon stimulation with anti-CD3/CD28 mAb coated microbeads 
(anti-CD3/CD28 beads, Fig. 3a, p < 0.05). Flow cytometry based TcR-Vβ analysis indicated a polyclonal expan-
sion pattern in both the CD28-superagonist and anti-CD3/CD28 beads stimulated Treg (Fig. 3b). In contrast to 
anti-CD3/CD28 bead stimulated Treg, the expression levels of FOXP3 and Helios were significantly increased 
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upon CD28-superagonist stimulation as compared to the IL-2 only culture condition (p < 0.01) (Fig. 3c). 
Likewise, a similar trend towards increased CTLA-4 expression was observed under CD28-superagonist stimula-
tory conditions. Moreover, the suppressor capacity (Fig. 3d) and TSDR demethylation (Fig. 3e) of Treg expanded 
by CD28-superagonist or anti-CD3/CD28 beads was similar. Notably, in line with CD28-agonist stimulation 
(as shown in Fig. 2c) and in contrast to anti-CD3/CD28 beads stimulated Treg, CD28-superagonist stimulated 
Treg showed a stable phenotype as evidenced by their low capacity to produce IFNγ (Fig. 3f and g). Although 
the percentage of IL-17A positive cells was not significantly reduced as compared to anti-CD3/CD28 beads stim-
ulation, the production of IL-17A and IFNγ appeared in culture supernatants were significantly low (Fig. 3g, 
p = 0.0068 for IL-17A, p = 0.0313 for IFNγ ). Taken together, this indicates that CD28-superagonist stimulation 
promotes proliferation of Treg while maintaining a stable Treg phenotype.
CD28-superagonist stimulation drives both naïve and memory Treg proliferation. It is debated 
whether naïve (CD4+ CD45RA+ CD25+ ) or rather memory-like (CD4+ CD45RA-CD25high) Treg are the ideal 
candidate cell population to be used for Treg-based cell therapy27,28. Therefore, we separated human Treg into naïve 
and memory-like subsets based on the expression of CD45RA using FACS sorting (see Supplementary Fig. S1) 
and stimulated the cells with CD28-superagonist or anti-CD3/CD28 beads in the presence of rhIL-2 as described 
above. Comparable to anti-CD3/CD28 beads stimulation, CD28-superagonist stimulation led to proliferation of 
both naïve and memory-like Treg as indicated by the expression of cell division marker KI67 (Fig. 4a). Phenotypic 
analysis showed that CD28-superagonist, like anti-CD3/CD28 beads stimulation, induced an almost complete 
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Figure 1. Single-CD28 stimulation induces Treg proliferation and promotes high level FOXP3 expression. 
Flow cytometry of FACS-sorted human Treg (CD4+ CD25high) that were labeled with CFSE and stimulated with 
soluble CD28 mAb, plate bound CD3 mAb or both (Anti-CD3+ CD28) in the presence of rhIL-2. As a control 
Treg cultured in the presence of rhIL-2 only were included. Cell division indicated by the dilution of CFSE 
(a), intracellular expression of FOXP3 (b) and active caspase 3 (c) were determined at day 7 of the cultures. 
Numbers within the histograms indicate the percentage of divided cells (a) and numbers within the quadrant 
show the percentage of positive cells (b,c). Cumulative data of Treg proliferation (a, right panel), the median 
fluorescence intensity (MFI) of FOXP3 (b, right panel), and the percentage of apoptotic cells (c) right panel) are 
also shown. Bar in cumulative data indicates the mean value. Kruskal-Wallis followed by Dunns post-hoc test 
(a) n = 3; b, n = 3) and Wilcoxon signed-rank test (c, n = 5) were used for statistical analysis. *P < 0.05.
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isoform switching from CD45RA to CD45RO in the naive Treg population (Fig. 4b). CD28 superagonist stimula-
tion led to a trend towards increased Helios expression levels (MFI), a key stabilizing Treg transcription factor29, 
in both naïve and memory-like Treg subsets while CD28 SA and anti-CD3/CD28 bead stimulated Treg revealed 
similar FOXP3 expression levels (Fig. 4c). Together this implies that CD28-superagonist is of interest for the ex 
vivo expansion of both naive and memory-like Treg.
The mTOR and PI3K pathways differentially regulate CD28-superagonist mediated Treg stability. 
CD28 stimulation is well known for its ability to activate the phosphoinositide-3 kinase (PI3K) pathway and 
its downstream targets such as mTOR30. To test if these signalling pathways are involved in CD28-superagonist 
mediated preservation of Treg, FACS sorted Treg were stimulated with the CD28-superagonist and exogenously 
added rhIL-2 in the absence or presence of a PI3K-inhibitor (wortmannin) or mTOR-inhibitor (rapamycin). In 
CD28-superagonist stimulated Treg the percentage of FOXP3 expressing cells was hardly influenced by PI3K or 
mTOR inhibition, but mTOR inhibition led to reduced FOXP3 expression levels per cell (p = 0.0541) (Fig. 5a). 
Regarding the cytokine producing potentials, PI3K inhibition led to a significant increase of IL-17A producing 
cells (Fig. 5b) and a similar trend was observed for IFNγ (Fig. 5b). mTOR-inhibition of CD28-superagonist stim-
ulated Treg seemed to further inhibit the IFNγ producing capacity while hardly influencing the IL17A producing 
potential (Fig. 5b). In contrast to CD28-SA stimulated Treg and as reported previously31,32, in anti-CD3/CD28 
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Figure 2. Single-CD28 stimulated Treg reveal a highly demethylated FOXP3 gene and profound suppressor 
function. (a) FACS-sorted human Treg were stimulated with soluble CD28 mAb, plate bound CD3 mAb 
or both (anti-CD3+ CD28) in the presence of rhIL-2 for 7-days. Thereafter, cells were harvested and the 
demethylation status of FOXP3 gene was analyzed using bisulfate sequencing. n = 6–7. (b) CFSE-labeled 
FACS-sorted Treg were stimulated as described above. The divided cells (CFSE low population) were re-sorted 
(left panel) at day 7 of the cultures, and subsequently their suppressive function was analyzed in a co-culture 
suppression assay. Overlay histograms show the inhibition of responder T cells (Tresp) proliferation following 
the addition of graded doses of Treg. Numbers indicate the percentage of divided responder T cells. Grey line: 
stimulated Tresp, Black line: co-cultured with Treg of interest. The ratio of Treg:Tresp are indicated on the 
top. Representative experiment of n = 3 individual experiments conducted with cells obtained from different 
donors are shown. (c) Intracellular staining of cytokine IL-17A and IFNγ after additional stimulation with 
PMA, ionomycin, and Brefeldin-A for 4 hours. Numbers within the quadrant indicate the percentage of positive 
cells. Dotplots show a representative experiment of n = 6–10 individuals as shown in the cumulative data graph 
(right panel). Kruskal-Wallis followed by Dunns post-hoc test was used for statistical analysis (a,c). *P < 0.05; 
**P < 0.01; ns: not significant.
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Figure 3. CD28-superagonist drives polyclonal Treg proliferation and enhances expression of FOXP3, 
Helios and CTLA-4. Flow cytometry of FACS-sorted human Treg that were stimulated with soluble CD28-
superagonist(CD28 SA) or anti-CD3/CD28 mAb coated microbeads (anti-CD3/CD28 beads) in the presence 
of rhIL-2. As a control Treg cultured in the presence of rhIL-2 only were included. (a) Fold expansion of 
Treg during 7 days of culture. n = 6–9. (b) TcR Vβ repertoire analysis following the indicated stimuli (see 
legend). One experiment of two similar ones conducted with cells obtained from different donors is shown. 
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stimulated Treg mTOR inhibition promotes FOXP3 expression (Fig. 5a). These findings suggest that the increase 
in FOXP3 expression and the reduced cytokine producing potential in CD28-SA stimulated Treg differentially 
depends on distal mTOR and proximal PI3K signaling of the PI3K-Akt-mTOR pathways respectively.
Discussion
For safe and effective clinical Treg-based immunotherapy, the ability to select and expand stable and highly 
suppressive Treg from the peripheral derived Treg pool is a prerequisite. In the present study, we show that 
single CD28-stimulation of human peripheral Treg results in polyclonal expansion and preservation of a sta-
ble Treg phenotype and function as indicated by high level FOXP3/Helios expression, reduced expression of 
pro-inflammatory cytokines and potent suppressor function. Moreover, single CD28-stimulation of Treg, in con-
trast to anti-CD3 and anti-CD28 stimulation, results in reduced plasticity as indicated by the reduced potential 
to produce IL-17A and the inability to produce IFNγ . CD28-superagonist stimulation drives polyclonal expan-
sion of peripheral Treg to a significantly higher level as compared to CD28-agonist and the standard anti-CD3/
CD28 mAb-beads stimulation. As well, CD28-superagonist stimulation promotes expansion of both naïve and 
memory-like Treg. Finally, using pharmaceutical inhibitors of mTOR and PI3K signaling pathways we reveal that 
both signaling molecules play a differential mechanistic role in CD28-superagonist mediated preservation of Treg 
stability. Together, our results demonstrate that CD28-superagonist stimulation could serve to improve Treg ex 
vivo expansion protocols to obtain sufficient numbers of stable committed Treg.
CD28 is the best-characterized costimulatory molecule on T cells. CD28 stimulation is crucial for optimal 
naive T cell activation, cytokine production, proliferation, and survival33. With regard to Treg, CD28 stimulation 
plays an important role in the development of FOXP3+ cells in the thymus as CD28 or CD28-ligand deficient 
mice reveal reduced numbers of naturally occurring Treg and hence develop severe autoimmunity18,19. Recent 
new insights obtained in CD28-conditional knockout mice, where CD28 expression in FOXP3+ Treg is post 
thymically affected, supports the notion that CD28 also plays an important role in the proliferation and survival 
of Treg after thymic generation20. Indeed, this specific CD28 deficiency in Treg resulted autoimmune disease was 
prevented by supplementation with wild type CD28 expressing Treg20. This made us realize that CD28 signaling 
might also play an important role in Treg homeostasis. Therefore we here addressed the question as to whether 
single-CD28 stimulation might drive stable expansion of human Treg. In fact, we demonstrate that single-CD28 
stimulation, in the absence of CD3 stimulation, as compared to anti-CD3/CD28 stimulated Treg, promotes supe-
rior Treg stability as indicated by increased FOXP3 expression and reduced production of pro-inflammatory 
cytokines.
Superagonistic CD28–specific mAbs are potent inducers of T cell proliferation both in vitro and in vivo in the 
absence of TCR engagement. Agonistic anti-rat CD28 mAb JJ316 supports large-scale expansion of rat CD4+ 
CD25+ Treg cells in the absence of T-cell receptor stimulation21,22 in vitro and prevents EAE and adjuvant arthri-
tis in rats34,35. These studies rationalized a phase I clinic trial of a humanized anti-human CD28-superagonist 
mAb, TGN1412, that lacked toxicity in non-human primates36. The trial was stopped due to rapid induction of 
multi-organ failure in six volunteers receiving the mAb that was likely caused by a cytokine storm. In our current 
work we have been studying ANC28.1mAb, a commercially available CD28-superagonist that possesses similar 
signaling signatures and functional properties as TGN141237. In contrast to our findings, it has been postulated 
that high purity FACS-sorted human Treg did not respond to ANC28.1 stimulation after 3 days26. However, it 
is generally known that high purity sorted Treg require more time and supplementation with exogenous rhIL-2 
to enter cell division. In fact, we here show that prolonged (7 days) stimulation of high purity sorted Treg by a 
CD28-superagonist in the presence of exogenously added rhIL-2 results in vigorous proliferation of both highly 
pure FOXP3+ naïve and memory-like Treg. Moreover, we found that all of the Treg input participated to pro-
liferation after CD28-superagonist stimulation in the presence of rhIL-2, indicating that CD28-superagonist 
stimulation result in polyclonal expansion of Treg. Importantly, these expanded Treg revealed high and stable 
FOXP3 expression, limited pro-inflammatory cytokines producing potential and potent suppressor capacity. 
Although CD28-superagonist stimulation is not specific for Treg, we clearly demonstrate the great potential of 
CD28-superagonist in stable ex vivo expansion of human Treg. Interestingly, it was recently demonstrated that 
in vitro stimulation of human PBMC by low-dose CD28 superagonist (TGN1412) selectively activated Treg24. 
Recent work from Brunstein et al. provided further support for a role for CD28 mediated activation in Treg 
expansion by showing that artificial antigen presenting cells modified to express CD86, the natural ligand of 
CD28, resulted in enhanced Treg expansion as compared to stimulation with anti-CD3/CD28 beads23. Despite a 
more pronounced stable phenotype of CD28 SA expanded Treg as indicated by the lower IL-17A/IFNγ cytokine 
producing potential as compared to anti-CD3/CD28 expanded Treg, CD28 SA and anti-CD3/CD28 expanded 
(c) Intracellular expression of FOXP3, Helios and CTLA-4 by Treg after 7 days stimulation (X-axis). Numbers 
within the histogram show the median fluorescence intensity (MFI). n = 6. (d) CFSE-based co-culture 
suppression assays showing a representative experiment of two independent ones. The ratio of Treg:Tresp are 
indicated at the top. Numbers indicate the percentage of divided responder T cells. Grey line: stimulated Tresp; 
Black line: co-cultured with CD28-superagonist or anti-CD3/CD28 beads expanded Treg. (e) Demethylation 
status of FOXP3 gene was analyzed using bisulfate sequencing. n = 3. (f) Intracellular staining of IL-17A and 
IFNγ at day 7 of the cultures. Numbers within the quadrant indicate the percentage of positive cells. Dot plots 
show a representative experiment of five individual ones conducted with cells obtained from different donors 
as shown in the cumulative data graphs; n = 5. (g) Measurement of IL-17A and IFNγ production in culture 
supernatants using luminex at day 7 of the cultures. n = 11 (for IL-17A) and n = 7 (for IFNγ ). Bar in cumulative 
data indicated the mean value. Kruskal-Wallis followed by Dunns post-hoc test was used for statistical analysis 
(a,c,e–g). *P < 0.05; **P < 0.01; ns: not significant.
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Figure 4. CD28-superagonist stimulation drives both naïve and memory Treg proliferation. Flow 
cytometry of FACS-sorted human naïve (CD4+ CD45RA+ CD25+ ) and memory (CD4+ CD45RA-CD25high) 
Treg that were stimulated with CD28-superagonist(CD28 SA) or anti-CD3/CD28 mAb coated-microbeads in 
the presence of rhIL-2. As a control Treg cultured in the presence of rhIL-2 only were included. Dotplots show 
intracellular staining of KI67 (a), isoform switch of CD45RA and CD45RO (b), and intracellular expression of 
FOXP3 and Helios (c). Numbers within (a) and (b) indicate the percentage of positive cells, and numbers within 
the histogram (c) indicate the MFI values. A representative example of n = 4 individual experiments conducted 
with cells obtained from different donors is shown. Aggregate data are shown in the figures at right side of the 
flow cytometry plots. Kruskal-Wallis followed by Dunns post-hoc test (a,b) and Wilcoxon signed-rank test  
(c) were used for statistical analysis. *P < 0.05; ***P < 0.001.
www.nature.com/scientificreports/
8Scientific RepoRts | 7:43003 | DOI: 10.1038/srep43003
Figure 5. PI3K and mTOR differentially regulate CD28-superagonist mediated Treg stability. Flow cytometry 
of FACS-sorted human CD4+ CD25high Treg that were stimulated with CD28-superagonist(CD28 SA) or 
anti-CD3/CD28 mAb coated-microbeads and exogenously added rhIL-2. The cells were pretreated for 30 minutes 
with the PI3K inhibitor wortmannin, or mTOR inhibitor rapamycin as indicated on the top. (a) Intracellular 
FOXP3 expression and (b) intracellular IL-17A and IFNγ staining at day 7 of the cultures. Numbers within the 
histogram indicate the MFI of FOXP3 and the percentage of positive cells, respectively (a), and numbers within the 
quadrants indicate the percentage of cytokine producing cells. A representative example of n = 5 (a,b) individual 
experiments conducted with cells obtained from different donors is shown. Aggregate data are shown in the figures 
bellow the flow cytometry plots. Wilcoxon signed-rank test was used for the comparison between medium group 
and inhibitor-treated group. *P < 0.05.
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Treg revealed similar in vitro suppressive potential (Fig.3). It has been demonstrated before that human cytokine 
producing Treg reveal similar suppressive capacity as Treg that do not produce cytokines12.
Both naïve (CD4+ CD45RA+ CD25+ ) and memory-like (CD4+ CD45RA-CD25high) Treg populations have 
been characterized in human peripheral blood38. It was suggested that naïve Treg would be the preferred starting 
population for the homogenous expansion of stable Treg27. Here we show that CD28-superagonist activation 
drives proliferation of naïve as well as memory-like Treg and results in a trend towards increased expression levels 
of Helios on both Treg subsets. Therefore, CD28-superagonist stimulation is of interest for the ex vivo expansion 
of both naive and memory-like Treg subsets.
CD28 activation is known to enhance PI3K activity and its downstream targets Akt and mTOR30, and the 
PI3K-Akt-mTOR signaling network regulates FOXP3 expression39. In mice PI3K signaling plays a dualistic role 
on Treg induction and Treg maintenance40–42. We here demonstrate that PI3K and mTOR signaling play a differ-
ential role in stabilizing Treg following CD28-superagonist stimulation as PI3K-inhibition restored the IL17A and 
IFNγ producing potential whereas mTOR inhibition reduced FOXP3 expression levels. In contrast, in anti-CD3/
CD28 stimulated Treg mTOR inhibition led to an increase in FOXP3 expressing cells and a reduced IFNγ pro-
ducing potential, whereas PI3K inhibition hardly affected the IL17A and IFNγ producing potential. Here we 
show that mTOR plays a role in increased FOXP3 expression of CD28-expanded Treg, while mTOR, as has been 
shown in anti-CD3/CD28 stimulated Treg, may negatively regulate FOXP3 expression. The latter is in line with 
previous work showing that mTOR inhibition by rapamycin of in vitro stimulated human FACS isolated natu-
rally occurring CD4+ CD25high Treg promotes selective outgrowth of FOXP3+ cells15,43. Apparently, multiple and 
different signaling pathways contribute to Treg stability in CD28-superagonist and CD3/CD28 beads expanded 
Treg. Together our findings indicate that PI3K and mTOR have a differential role in promoting the stability of 
CD28-expanded human peripheral Treg.
Summarizing, here we demonstrate that CD28-superagonist mediated ex vivo expansion of human Treg, 
which mechanistically depends on differential PI3K and mTOR-signalling, might be a promising new avenue 
for the expansion of stable polyclonal Treg intended for Treg-based immunotherapy in transplantation and 
autoimmunity.
Methods
Cell isolation. Peripheral blood mononuclear cells (PBMCs) were isolated using density gradient centrif-
ugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) from buffy coats of healthy blood donors, pur-
chased from Sanquin Blood Supply Foundation, region South-East, Nijmegen, the Netherlands. Buffy coats were 
obtained upon written consent from the donor for scientific use according to the Dutch law. CD4+ cells were 
isolated by negative selection using RosetteSepTM human CD4+ cell enrichment cocktail (Stemcell, Cologne, 
Germany). Thereafter, enriched CD4+ cells were labeled with anti-CD25-PeCy7 (M-A251; BD Biosciences, 
Breda, Netherlands) conjugated mAb. Thereafter, CD4+ CD25high Treg were sorted using a FACSAria cell-
sorter (BD Bioscience). In case of naïve and memory Treg sorting, CD4+ cells were labeled with anti-CD25-Pe-
Cy7(M-A251) and anti-CD45RA-pacific blue (HI100, Biolegend, San Diego, CA, USA) mAbs; thereafter CD4+ 
CD45RA+ CD25+ naïve Treg and CD4+ CD45RA-CD25high memory Treg were sorted using a FACSAria cell-
sorter. Cell purity was typically over 97%.
Cell culture. Treg were stimulated with rhIL-2 (25 U/mL) alone as control, or together with either soluble 
CD28 agonist mAb (1 μ g/mL, Clone L293, Cat# 348040; BD Bioscience), plate-bound CD3 mAb (5 μ g/mL, Clone 
UCHT1, BD Bioscience), plate-bound CD3 (5 μ g/mL) plus soluble CD28 mAb (1μ g/mL), CD28-superagonist 
ANC28.1 (1 μ g/mL, Clone ANC28.1/5D10, Cat# 177–820, preservative free; Ancell, Bayport, USA), or anti-CD3/
anti-CD28 mAb-coated microbeads (Invitrogen by Life technologies, Bleiswijk, The Netherlands) used in a 1:2 
bead-to-cell ratio. Titration of soluble CD28-agonist and CD28-superagonist antibodies at a concentration range 
of 1–10 μ g/mL led to similar FOXP3 expression levels as determined by flow cytometry. Cells were cultured 
in 96-well round bottom plates in RPMI 1640 (Invitrogen) as described previously44. In selected experiments 
immunomodulating agents were analyzed; Treg were pretreated with wortmannin (5 μ M), rapamycin (200 nM) 
(Sigma-Aldrich, St. Louis, USA)15, or vehicle control for 30 min at 37 °C. Thereafter, stimulators as indicated were 
added to the culture mixture.
Flow cytometry, antibodies and CFSE labelling. Cells were phenotypically analyzed using 
multi-color flow cytometry (Beckman-Coulter, Brea, CA, USA). Antibodies used for flow cytometry 
include: anti-CD3-PeCy5 (UCHT1), anti-CD4-PC5.5 (13B8.2), anti-CD27-PC5.5 (1A4CD27) (all from 
Beckman-Coulter), anti-CD25-PeCy7 (M-A25, BD). Anti-FOXP3-eFluo660 (PCH101) or -eFluo450 (PCH101), 
anti-IL-17A (eBio64DEC17)-AlexFluo88 and anti-IFNγ (4S.B3)-Pcy7 (all from eBioscience, San Diego, USA), 
anti-Helios-AlexFluo647 (22F6, Biolegend), anti-CTLA4-PE (BNI3) and anti-active caspase 3-PE (C92–605) 
(both from BD) were used after Fix-Perm-treatment (eBiosciences). Appropriate isotype mAbs were used to 
define marker settings. Fixable viability dye eFluor® 780 (eBioscience) was used in some experiments. Data were 
analyzed using Kaluza software (Beckman-Coulter).
To measure the intracellular cytokine producing potential, the cells were stimulated with PMA (12.5 ng/mL) 
plus ionomycin (500 ng/mL) in the presence of Brefeldin-A (5 μ g/mL) for 4 hours before analysis. To analyze the 
TCR-Vβ repertoire by flow cytometry we used a TCR-Vβ kit (Betamark, Beckman-Coulter) according to the 
manufacturer’s instructions. To monitor cell division by flow cytometry, cells were labeled with 0.5 μ M CFSE 
(Invitrogen) and analyzed by flow cytometry as described previously45.
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Cytokine detection assay. IL-17A and IFNγ were determined in the culture supernatants using Luminex 
cytokine assays (Invitrogen), according to the manufacturer’s instructions. The lower level of detection of IFNγ 
was < 5 pg/mL and that of IL-17A was < 10 pg/mL.
Co-culture suppression assays. The suppressor capacity of expanded-Treg was studied in co-culture sup-
pression assays. Treg were cultured for 7 days under the conditions described above. Thereafter, viable Treg were 
collected, washed and added at different ratios to CFSE-labeled CD4+ CD25- responder cells (Tresp) together 
with anti-CD3/anti-CD28 mAb-coated beads at a bead-to-cell ratio of 1:5 for 3 days. Proliferation of Tresp was 
determined by analyzing CFSE dilution as described previously45.
FOXP3 gene methylation. The methylation status of FOXP3 gene was analyzed by bisulphate sequenc-
ing, as described previously46. In brief, geneGenomic DNA was isolated from Treg using the QIAamp 
DNABloodMini kit (Qiagen, Venlo, Netherlands), Bisulfite converted and amplified using bisulfite-specific 
polymerase chain reaction (PCR) (forward 59 TGGATATTTGGTTAGAGTTAA GAAT 39 and reverse 59 
ACCTAACACTCTCAAAACTTCAAAC 39). The purified PCR product was sequenced on an ABI 3130 Genetic 
Analyzer (Applied Biosystems by Lifetechnologies), and analyzed using Sequencing Analysis version 5.4 software.
Cumulative methylation status data is presented as demethylation index, calculated by percentage of demeth-
ylation after Treg culture/percentage of demethylation of the input Treg population. Percentage of demethylation 
of FACS-sorted input Treg is typically > 95%46.
Statistics. Data derived from two or more than two groups with non-normal distributions were compared 
using Wilcoxon matched-pairs test or Kruskal-Wallis test, respectively. The multiple comparisons were adjusted 
with a Dunns post-hoc test to compare groups involved. P < 0.05 was considered statistically significant. These 
statistical tests were performed in GraphPad Prism 5.0 for Windows (GraphPad Software Inc., La Jolla, USA).
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